Shares of Celgene Corporation (CELG) advanced to $117.01. The price had gained 0.74% or 0.86 points intraday. The latest trading session witnessed $100.18 million in upticks and $106.65 million in downticks, resulting in net money flow of (-6.47) million. The up/down ratio for the day stood at 0.94. On a weekly scale, the price has seen a change of 2.98%. From the trading data available, it was disclosed that a block trade of negative money flow worth $(-5.2) million occurred during the day. $10.98 million in uptick and $16.17 million in downtick were the highlight of the block transaction which had an up/down ratio of 0.68.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Celgene Corporation rose by 3.01% in the last five trading days and 1.43% for the last 4 weeks. Celgene Corporation is up 14.91% in the last 3-month period. Year-to-Date the stock performance stands at 1.43%. Celgene Corporation (NASDAQ:CELG) rose 1.08% or 1.26 points on Wednesday and made its way into the gainers of the day. After trading began at $116.11 the stock was seen hitting $117.68 as a peak level and $115.26 as the lowest level. The stock ended up at $117.41. The daily volume was measured at 4,674,361 shares. The 52-week high of the share price is $127 and the 52-week low is $93.05. The company has a market cap of $91,017 million.
Company has reported several Insider transactions to the SEC, on Nov 30, 2016, Rupert Vessey (officer ) sold 2,500 shares at 123.18 per share price.On Nov 15, 2016, Michael F. Pehl (officer ) sold 22,052 shares at 121.09 per share price.On Nov 14, 2016, Robert J Hugin (director officer ) sold 100,000 shares at 120.00 per share price.
Celgene Corporation Last issued its quarterly earnings results on Jan 26, 2017. The company reported $1.61 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $1.60. The company had revenue of $2980.50 million for the quarter, compared to analysts expectations of $3021.34 million. The companys revenue was up 16.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.18 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Celgene Corporation was Downgraded by Standpoint Research to Hold on Nov 9, 2016. Celgene Corporation was Initiated by Mizuho on Nov 8, 2016 to Buy, Price Target of the shares are set at $130.
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.